Drugs / polyvalent antigen-KLH conjugate vaccine
re-read 2 minutes ago

polyvalent antigen-KLH conjugate vaccine

Vaccine

Developed for
fallopian tube cancer · ovarian cancer · peritoneum cancer
Investigated by
Gynecologic Oncology Group · National Cancer Institute (NCI)

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00693342 fallopian tube cancer, ovarian cancer, peritoneum cancer Gynecologic Oncology Group Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as polyvalent antigen-KLH conjugate vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00693342
Modality Vaccine “polyvalent antigen-KLH conjugate vaccineNCT00693342